Mallinckrodt and Rubicon to develop PanExcea

August 21, 2008

CRO Rubicon Research and chemicals manufacturer Mallinckrodt Baker are teaming up to develop the PanExcea excipient range, which was launched by the latter firm’s parent company Covidien in July.

The current expansion of the pharmaceutical excipient sector, which a BCC Research report estimated would grow to $4.3bn (€2.8bn) by 2011, suggests that drugmakers are beginning to focus on this aspect of product development as an effective means of controlling development expenditure.¹

¹Outsourcing-Pharma.com

read more | digg story

Bookmark and Share


US market for stem cell technologies in next 5 years

August 12, 2008

According to a new technical market research report, STEM CELL TECHNOLOGY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS (BIO035C) from BCC Research, the domestic market for stem cell technology is expected to increase from $112.0 million in 2007 to $423.1 million in 2012, a compound annual growth rate (CAGR) of 30.5%

The market is divided into cellular therapeutics and therapeutic banking categories. Stem cells in therapeutic banking have the larger share of the market, worth $65.9 million in 2007 and expected to increase to $155.7 million in 2012, for a CAGR of 18.8%.

Cellular therapeutics should be the faster growing segment. Cellular therapeutics generated $46.1 million in 2007 and is expected to generate $267.4 million in 2012, a CAGR of 42.1%.

read more | digg story

Bookmark and Share


Global Market for DNA Sequencing Worth $1.7 Billion by 2013

August 11, 2008

Wellesley, Mass—According to a new technical market research report, DNA SEQUENCING: EMERGING TECHNOLOGIES AND APPLICATIONS (BIO045B) from BCC Research, the global market for DNA sequencing technology was worth $794.0 million in 2007 and an estimated $862.5 million in 2008. This should increase to $1.7 billion by 2013, a compound annual growth rate (CAGR) of 14.7%.

The market is broken down into the segments of research/drug discovery and development, commercial applications and emerging applications. Research/drug discovery and development has the largest share of the market, generating $600.4 million in 2007. This is expected to increase to $640.6 million in 2008 and over $1.0 billion in 2013, for a CAGR of 9.7%.

Commercial applications have the next largest share of the market, worth $193.6 million in 2007 and an estimated $218.8 million in 2008. This should increase at a CAGR of 14.3% to reach $426.1 million in 2013.

Emerging applications have the smallest but fastest growing share of the market. This sector is expected to generate $3.1 million by the end of 2008 and $272.5 million in 2013, for a CAGR of 144.8%.

DNA sequencing allows us to catalogue the variations within the human genome sequence that make us phenotypically different, and that cause resistance and susceptibility to disease. The rapidly evolving sequencing technologies provide unprecedented analytical tools that allow us to identify this sequence variation, in humans as well as in other species.

Technology and market forces are working a fundamental shift in the DNA sequencing industry away from stagnant/declining growth towards high growth. This growth inflection signals the arrival of DNA sequencing as a premier genetic analysis tool: useful for existing applications such as de novo whole genome sequencing and entirely new applications like epigenetic tag sequencing.

FIGURE
GLOBAL VALUE OF DNA SEQUENCING, BY END USE APPLICATION,
2006-2013
($ millions)

read more | digg story

Bookmark and Share


$300m shot in the arm for Merck’s vaccines plant

July 24, 2008

US drug giant Merck & Co hopes that an additional $300m investment in its vaccine manufacturing plant in Durham, North Carolina will cement its position at the forefront of the global vaccines market.¹

¹Gareth McDonald; In-PharmaTechnologist.com

read more | digg story

Bookmark and Share


Global Market For Pharmaceuticals Worth More Than $1 Trillion By 2013

June 30, 2008

According to a new technical market research report, GLOBAL PHARMACEUTICAL MARKETS (PHM037B) from BCC Research, the global market for pharmaceuticals was worth $693.6 billion in 2007. This is expected to increase to $737.6 billion in 2008 and reach over $1.0 trillion in 2013, a compound annual growth rate (CAGR) of 6.9%.

The market is broken down into applications of branded prescription drugs, generic prescription drugs and over-the-counter (OTC) products. Of these, branded prescription drugs have the largest share of the market. Worth an estimated $525.1 billion in 2007, this segment is expected to grow to a value of $553.2 billion in 2008 and $741.5 billion by the end of 2013, for a CAGR of 6.0%.

The second largest segment, generic prescription drugs, will experience the highest growth rate over the study period. Worth $78.5 billion in 2007 and an estimated $88.7 billion in 2008, it will reach $151.4 billion by the end of 2013, for a CAGR of 11.3%.

The OTC segment was worth over $90.0 billion in 2007. It should increase to $95.7 billion in 2008 and reach $135.1 billion in 2013, for a CAGR of 7.1%.

Though the worldwide pharmaceutical industry remains one of the most profitable and stable industries, several variables are influencing fundamental changes in its structure including increasing examples of government-imposed price reductions in pharmaceutical prices, the increasing role of generic substitutes, and enhanced outsourcing, in-licensing, contract research and manufacturing activities.

Increased health awareness amongst patients and governments, changing world demographics, declining R&D productivity, worldwide compliance of general agreements on tariffs and trade (GATT) and trade related intellectual property rights (TRIPS), along with the emergence of e-pharmaceuticals also are reshaping the dynamic pharmaceuticals industry.¹

¹BCC Research

read more | digg story

Bookmark and Share


BASF signs up to USP certification scheme

June 23, 2008

BASF’s drug excipient manufacturing site in Geismar, Louisiana in the USA has been accredited under the US Pharmacopoeia’s (USP) voluntary certification scheme. ¹

¹Gareth Macdonald, In-pharma Technologist.com

read more | digg story

Bookmark and Share


Industry Insider: A click closer to Rx information

June 12, 2008

More consumers are going online to look up information about medications, and they’re more likely to click on prescription drug ads they find there, a new survey about direct-to-consumer ads in the pharmaceutical industry found.¹

¹Jeff May and Robert Cohen/The Star-Ledger

read more | digg story

Bookmark and Share